Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revance Awaits Mylan Decision On Botox Biosimilar

Potential For Market Entry In 2025 If Collaboration Continues

Executive Summary

Revance Therapeutics is evaluating its options for developing a biosimilar version of Allergan’s globally renowned Botox cosmetic brand, as it waits for Mylan to decide whether to press on with the opportunity or opt out, per terms agreed last August.

You may also be interested in...



Mylan Makes Decision On Potential First Botox Biosimilar

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Mylan Still Mulling Revance's Botox Biosimilar

Revance says it is still in discussions with Mylan on whether or not the pair will proceed with their collaboration on a biosimilar version of Botox, despite an extended deadline for a commitment on the deal having passed on 30 April.

Mylan Reforms As It Prepares To Become Viatris

Mylan is pushing ahead with reforms that include wide-ranging product rationalization in the US, refocusing its commercial resources and cutting development and manufacturing costs. These reforms are intended to run prior to and concurrently with the group’s merger with Pfizer’s Upjohn unit to form Viatris.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel